MedTrace Logo

Anti-VEGF in Real-world

NCT05222633 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-02-03

No results posted yet for this study

Summary

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Conditions

Interventions

DRUG

Ranibizumab

Ranibizumab 0.5mg/0.05ml intravitreal injection

DRUG

Aflibercept

Aflibercept 2.0mg/0.05ml intravitreal injection

DRUG

Conbercept

Conbercept 0.5mg/0.05ml intravitreal injection

Sponsors & Collaborators

  • Wenbin Wei

    lead OTHER

Principal Investigators

  • Wenbin Wei, MD · Beijing Tongren Hospital

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-01-01
Completion
2023-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05222633 on ClinicalTrials.gov